scPharmaceuticals Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense
Amortization expense - right-of-use leased assets - operating
Accretion expense
Loss on disposal of property and equipment
Reduction in carrying value of operating right-of-use lease assets
Accretion on short-term investments
Allowance for doubtful accounts
Allowance for excess, damaged and obsolete inventory
Stock-based compensation
Non-cash interest expense
Fair value adjustment to term loan
Fair value adjustment to revenue purchase and sale liability
Fair value adjustment to derivative liability
Debt issuance costs
Loss on extinguishment of debt
Changes in operating assets and liabilities
Accounts receivable
Inventory
Prepaid expenses and other assets
Accounts payable, accrued expenses and other liabilities

Net cash flows used in operating activities
Cash flows from investing activities
Purchases of property and equipment
Maturities of short-term investments
Purchases of short-term investments
Net cash flows provided by investing activities
Cash flows from financing activities
Proceeds from common stock offering, net of underwriter discounts and offering costs
Proceeds from term loan, net
Proceeds from revenue participation agreement, net
Proceeds from employee stock purchase plan
Proceeds from at-the-market offering, net
Principal payments on term loan
Prepayment and legal fees
Payment of term loan final fee
Payment of term loan exit fee
Payments on revenue participation agreement
Settlement of restricted stock units for tax withholding obligations
Net cash flows provided by financing activities

Net (decrease) increase in cash
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Supplemental cash flow information
Interest paid
Taxes paid
Supplemental disclosure of non-cash activities
Fair value of warrants issued
Operating right-of-use asset received in exchange for lease obligations
Transfer of issuance costs from other noncurrent assets to equity

Comments